

Gemini Stock Analysis Report

Based on the "Stock Detailed Analysis Report" provided for **SUNPHARMA.NS** (Sun Pharmaceutical Industries Ltd.), here is my assessment from the perspective of a risk-averse Positional Equity Trader.

Note on Data Context: The report indicates a generated date of **2026-01-31**. All analysis below treats this date and the associated pricing/chart data as the current reality for the trade setup.

Step 1: Audit the Data

- **Data Present:**
 - **Price Action:** Daily and Weekly candlestick charts, 3-year history.
 - **Trend Indicators:** EMA 20, 50, 200; Supertrend; MACD.
 - **Oscillators:** RSI (14), Bollinger Bands.
 - **Volume:** Volume bars, Moving Averages, and distribution/accumulation analysis.
 - **Relative Strength:** Comparison against [^]CNXP_{PHARMA} and composite scoring.
 - **Fundamentals:** Snapshot of 4-year and 6-quarter growth metrics.
 - **Data Missing:**
 - **Specific Fibonacci Levels:** While visual estimation is possible, precise retracement levels are not explicitly tabulated.
 - **Sector Breadth:** While RS against the sector is present, broader market context (Nifty 50 correlation) is limited.
 - **Confidence Level: High.** The report provides a comprehensive technical suite sufficient for positional trading decisions.
-

Step 2: Analyze the Setup

- **Price Structure & Trend (Bearish):**
 - The stock is in a confirmed **Downtrend**. The current price (1595.30) is trading below the EMA 20 (1664), EMA 50 (1701), and the critical EMA 200 (1696).
 - The price is making lower lows and lower highs on the daily chart (Page 2, Page 21).
 - The **Supertrend** is negative (Sell signal active since Dec 2025).
- **Momentum (Weak):**
 - **RSI is 29.33** (Page 16), which is deeply **Oversold**. While this often precedes a bounce, in a strong downtrend, an asset can remain oversold for extended periods ("imbedded oversold").
 - **MACD** is negative, with the histogram showing sustained bearish momentum (Page 12).
 - **Relative Strength** is poor (47.7/100) and lagging the sector (Page 4).
- **Volume Analysis (Bearish):**
 - The report notes "38 Signals Detected" regarding volume, with recent days marked as "Distribution Days" (Page 18). This indicates institutional selling on strength.
- **Fundamentals (Deteriorating):**
 - Short-term fundamental analysis (Page 3) shows Net Income and ROE are **not growing** on a Quarter-over-Quarter basis, providing a fundamental justification for the price decline.

Conclusion of Setup: This is currently a "Falling Knife." There is no confluence to support a long position yet. The stock has broken the long-term trend (trading below EMA 200) and has no reversal structure in place.

Gemini Stock Analysis Report

Step 3: Formulate the Recommendation

Recommendation: **NO** (Do not enter now).

Reasoning: The stock is technically broken on the daily timeframe. Entering now is counter-trend trading, which violates the principles of intermediate-term positional trading. The confluence of "Price < EMA 200", "Distribution Volume", and "declining Net Income" creates a high-risk environment. The Oversold RSI (29) suggests a potential "dead cat bounce," but not a durable trend reversal yet.

Conditional Plan (Watchlist)

Rationale: We are waiting for the stock to stabilize and reclaim short-term momentum before entering.

Condition to Buy:

1. Price must successfully form a base (support) around the **1500-1550** level (historical support seen on 3-year chart).
2. Price must Close **above the EMA 20** (currently ~1664) to indicate short-term selling pressure has abated.
3. RSI must recover above 40.

Entry Price: **INR 1670 - INR 1675** (Only on a daily close above the 20 EMA).

- **Stop Loss:** **INR 1580** (Below the recent swing low/potential support zone).
- **Take Profit:** **INR 1800** (Upper Bollinger Band and previous congestion zone).
 - *Risk/Reward Ratio:* ~1.4 (Acceptable, but not stellar. Ideally, wait for the EMA 20 to flatten out to tighten the stop loss).

News & Analyst Targets

As a stock research analyst, I have compiled the latest news, brokerage updates, and analyst targets for **Sun Pharmaceutical Industries Ltd. (SUNPHARMA)** as of Saturday, **January 31, 2026**.

1) Latest News for SUNPHARMA (Week of Jan 26 - Jan 31, 2026)

- **Q3 FY26 Results Announcement (Today):** Sun Pharma is scheduled to announce its financial results for the quarter ended December 31, 2025 (Q3 FY26) today, **Saturday, January 31, 2026**. The company will host an earnings call at **06:30 PM IST** to discuss the performance.
 - *Expectations:* Brokerage previews estimate a **moderate revenue growth of ~3-7% YoY**, driven by strong domestic formulations and emerging markets. However, **Net Profit is expected to decline by ~4-6% YoY** (to approx. INR 3,040 Cr) due to softness in the US generics business (impact of lower Revlimid sales) and higher specialty spending (Leqselvi launch costs).
- **Interim Dividend & Record Date:** The Board of Directors is meeting today to consider the declaration of an interim dividend for FY 2025-26. The company has already fixed **Thursday, February 5, 2026**, as the **Record Date** for determining the eligibility of shareholders for this dividend.
- **Semaglutide Approval:** Earlier in January, Sun Pharma announced it received regulatory approval to launch a generic version of **Semaglutide** (a popular weight-loss drug) in India. The launch is expected after the patent expires in March 2026, positioning Sun to capture a significant share of the obesity management market.

Gemini Stock Analysis Report

2) Upgrade or Downgrade from Brokerages

There have been no major *rating changes* (upgrades/downgrades) specifically during this current week (Jan 26-31), as most analysts are waiting for the Q3 results release today. However, recent sentiment remains mixed to positive:

- **Choice Equity Broking (Jan 22, 2026):** Issued a recommendation highlighting a potential upside of ~11.6%, citing strong technicals and fundamental growth drivers.
- **Previous Context:** Major global brokerages like **Jefferies** have maintained a "**Buy**" rating (target INR 2,070) in recent months, focusing on the company's specialty portfolio transition. Conversely, some brokerages like **Bank of America** had downgraded the stock to "Underperform" earlier in FY26 (Aug 2025) due to valuation concerns, a stance that some conservative analysts still echo ahead of today's results.

3) Other News Impacting SUNPHARMA

- **SPARC Court Ruling (Positive Indirect Impact):** Sun Pharma's research arm, **Sun Pharma Advanced Research Company (SPARC)**, recently received a favorable ruling from a US court regarding its "Sezaby" Priority Review Voucher. This has led to a rally in SPARC shares, which sentimentally benefits Sun Pharma given their close association and Sun's stake in SPARC's pipeline.
- **Acquisition Rumors Denied:** On **January 19, 2026**, Sun Pharma officially denied speculative news reports that it was planning to acquire **Organon** for \$10 billion. The company clarified there were no such negotiations, which helped settle recent stock volatility caused by the rumor.
- **US Specialty Business Focus:** Revenue from Sun's innovative (specialty) medicines business recently overtook its generics business in the US for the first time in Q2 FY26. Analysts are closely watching today's Q3 results to see if this trend continues, specifically looking for growth numbers from key drugs like **Ilumya** (psoriasis), **Cequa** (dry eye), and **Winlevi** (acne).

4) Latest Analyst Targets

Below is a summary of the latest available price targets from major brokerages. Please note that these targets may be revised *after* the Q3 results are declared tonight.

Brokerage Firm	Rating	Price Target (INR)	Outlook / Comments
Jefferies	Buy	2,070	Bullish on specialty portfolio & India volume growth.
Emkay Global	Buy	2,000	Expects strong domestic traction to offset US generics weakness.
Motilal Oswal	Buy	1,960	Positive on long-term specialty asset monetization.
ICICI Direct	Buy	1,965	sees steady compounding in India business.
Consensus	Buy	1,965	Average of ~38 analysts (Investing.com data)
Nuvama	Hold	1,830	Cautious on near-term US generic pricing pressure.

Gemini Stock Analysis Report

Analyst Note: The stock is currently trading near **INR 1,630 - INR 1,640**. The focus for the upcoming week will be the management commentary on **specialty R&D spend** and the **US pricing environment** for FY27.


Stock Detailed Analysis Report

SUNPHARMA.NS

Current Price: ₹1595.30

Generated: 2026-01-31 11:34

SUNPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

SUNPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index: ^CNXPHARMA

Sector: Pharma

Classification: **Neutral**

RS Score: 47.7/100

:

== RS RATIOS ==:

1M RS: **0.965 [Neutral]**

3M RS: **0.960 [Neutral]**

6M RS: **0.973 [Neutral]**

1Y RS: **0.890 [Neutral]**

:

== TURNAROUND ANALYSIS ==:

Turnaround Status: **Not Detected**

:

SIGNAL CRITERIA::

✓ **Emerging RS:** 1M (0.965) > 3M (0.960)


✓ **Medium-term Lagging:** 6M=0.973, 1Y=0.890 (≤ 1.0)

✗ **Performance Improving:** **Not improving**


Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA

Classification: Neutral


Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1664.37
EMA 50:	1701.53
EMA 200:	1696.34
Trend Status:	Short-term Downtrend
Golden Cross Date:	2025-11-14 00:00:00+05:30
Golden Cross Price:	1757.10


SUNPHARMA.NS EMA Crossover Analysis



SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1595.30
Upper Band:	1804.78
Middle Band (SMA 20):	1681.38
Lower Band:	1557.98
%B:	0.1512
Band Width:	0.1468
Status:	Lower Half
Signal:	None
Recent Signal 1:	Buy Signal at 2025-12-30 00:00:00+05:30
Recent Signal 2:	Buy Signal at 2026-01-20 00:00:00+05:30
Recent Signal 3:	Buy Signal at 2026-01-21 00:00:00+05:30


SUNPHARMA.NS Bollinger Bands (20, 2) Analysis



SUNPHARMA.NS - Supertrend Summary

Status:	DOWNTREND (Sell)
Supertrend Value:	1715.95
Signal Identified On:	2025-12-18


Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




SUNPHARMA.NS - MACD Summary

MACD Line:	-39.04
Signal Line:	-30.88
Histogram:	-8.16
Trend:	Bearish
Momentum:	Weakening
Signal:	None

SUNPHARMA.NS Price






SUNPHARMA.NS MACD (12, 26, 9)



SUNPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.1468
ATR:	40.0500
Total Signals:	10
Signal 1:	BB Squeeze at 2025-12-15 00:00:00+05:30 (Price: 1797.10)
Signal 2:	BB Squeeze at 2025-12-16 00:00:00+05:30 (Price: 1781.30)
Signal 3:	BB Squeeze at 2025-12-17 00:00:00+05:30 (Price: 1792.90)
Signal 4:	ATR Contraction at 2026-01-02 00:00:00+05:30 (Price: 1728.00)
Signal 5:	ATR Contraction at 2026-01-05 00:00:00+05:30 (Price: 1728.90)


SUNPHARMA.NS - Volatility Squeeze Analysis



SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	29.33
Current Volume:	3962126
Volume MA 20:	2666524
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-06-04 00:00:00+05:30, Price: 1659.44
Bearish Div 1:	Date: 2024-04-01 00:00:00+05:30, Price: 1609.07
Bearish Div 2:	Date: 2025-07-30 00:00:00+05:30, Price: 1733.80

SUNPHARMA.NS RSI-Volume Divergence Analysis



SUNPHARMA.NS - Volume Analysis

== VOLUME ANALYSIS ==:

Status:

38 Signals Detected

:

2025-12-26 [-]:

Distribution Day

2025-12-29 [+]:

Selling Exhaustion (Bullish Div)

2026-01-08 [-]:

Distribution Day



2026-01-21 [-]:

Distribution Day

2026-01-29 [-]:

Distribution Day

SUNPHARMA.NS - Volume Analysis



Multi-Timeframe Supertrend Analysis

Timeframe	Status	Value	Last Price	Signal Date
1 Week	DOWNTREND (Sell)	1761.01	1595.3	2026-01-12
1 Day	DOWNTREND (Sell)	1715.95	1595.3	2025-12-18
15 Min	UPTREND (Buy)	1589.26	1595.3	2026-01-30

Multi-Timeframe MACD Analysis

Timeframe	Trend	Momentum	Signal
1 Week	Bearish	Strengthening	No Signal
1 Day	Bearish	Weakening	No Signal
15 Min	Bullish	Weakening	No Signal

SUNPHARMA.NS - 1 Week (Candlestick + EMAs)




SUNPHARMA.NS - 1 Day (Candlestick + EMAs)




SUNPHARMA.NS - 15 Min (Candlestick + EMAs)



Trendlyne Snapshot - SUNPHARMA_main



Trendlyne Snapshot - SUNPHARMA_forecaster



Sun Pharmaceutical - SUNPHARMA - stock price prediction, stock forecast, target price, analyst ratings from 38 analysts

Sun Pharmaceutical has a share price target of Rs 1965, revenue growth forecast of 9.2%, and profit growth estimate of 2.8% for FY26, based on top 38 analyst calls.



Upgrade Your Plan

You need to upgrade your subscription plan to access this feature

[Upgrade Now](#)[Sign in](#)

SAMPLE DATA BELOW

